A record of what Jefferies Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Upgraded Biocon from 'Underperform' to 'Hold' with a revised target price of ₹400, up from ₹280. This reflects a more positive outlook due to recent US FDA clearance for Biocon's Bengaluru biologics plant, enabling US market supply, and the approval of bStelara, slated for a February 2025 launch. These developments address previous concerns about regulatory hurdles and growth uncertainty.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
BioconNeutralCalled 07 Jan 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Jefferies Analysis’s full track record